MX2018004192A - Formulaciones de análogos de proteína relacionada con la hormona paratiroidea (pthrp), parches transdérmicos de las mismas y usos de las mismas. - Google Patents
Formulaciones de análogos de proteína relacionada con la hormona paratiroidea (pthrp), parches transdérmicos de las mismas y usos de las mismas.Info
- Publication number
- MX2018004192A MX2018004192A MX2018004192A MX2018004192A MX2018004192A MX 2018004192 A MX2018004192 A MX 2018004192A MX 2018004192 A MX2018004192 A MX 2018004192A MX 2018004192 A MX2018004192 A MX 2018004192A MX 2018004192 A MX2018004192 A MX 2018004192A
- Authority
- MX
- Mexico
- Prior art keywords
- formulations
- patches
- bone
- transdermal patches
- methods
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 101150071808 PTHLH gene Proteins 0.000 title 1
- 208000010392 Bone Fractures Diseases 0.000 abstract 2
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 abstract 2
- 102000043299 Parathyroid hormone-related Human genes 0.000 abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 206010049088 Osteopenia Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 230000037317 transdermal delivery Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen formulaciones de análogos de PTHrP para la administración transdérmica de una cantidad eficaz para uso terapéutico de un análogo de PTHrP, así como también parches transdérmicos mediante el uso de estas formulaciones, métodos de preparación de las formulaciones y parches descritos, y métodos de uso de estas formulaciones y parches para tratar la osteoporosis , la osteopenia, la osteoartritis, y/o una fractura ósea, mejorar la densidad mineral ósea (BMD), mejorar la puntuación de hueso trabecular (TBS), y tratar, prevenir y/o reducir las fracturas óseas.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562239801P | 2015-10-09 | 2015-10-09 | |
US201562239774P | 2015-10-09 | 2015-10-09 | |
US201562239773P | 2015-10-09 | 2015-10-09 | |
US201662324336P | 2016-04-18 | 2016-04-18 | |
US201662353249P | 2016-06-22 | 2016-06-22 | |
US201662396196P | 2016-09-18 | 2016-09-18 | |
PCT/US2016/056196 WO2017062922A1 (en) | 2015-10-09 | 2016-10-08 | Formulations of pthrp analogues, transdermal patches thereof, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018004192A true MX2018004192A (es) | 2018-09-26 |
Family
ID=58488710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018004192A MX2018004192A (es) | 2015-10-09 | 2016-10-08 | Formulaciones de análogos de proteína relacionada con la hormona paratiroidea (pthrp), parches transdérmicos de las mismas y usos de las mismas. |
Country Status (22)
Country | Link |
---|---|
US (1) | US20190091138A1 (es) |
EP (2) | EP3909566A1 (es) |
JP (3) | JP6867379B2 (es) |
KR (1) | KR20180067573A (es) |
CN (2) | CN108697881A (es) |
AU (2) | AU2016334378B2 (es) |
BR (1) | BR112018007159A2 (es) |
CA (1) | CA3000533C (es) |
CY (1) | CY1124657T1 (es) |
DK (1) | DK3359241T3 (es) |
ES (1) | ES2881461T3 (es) |
HR (1) | HRP20211127T1 (es) |
HU (1) | HUE055658T2 (es) |
IL (2) | IL287604B2 (es) |
LT (1) | LT3359241T (es) |
MX (1) | MX2018004192A (es) |
PL (1) | PL3359241T3 (es) |
PT (1) | PT3359241T (es) |
RS (1) | RS62394B1 (es) |
SG (1) | SG11201802871UA (es) |
SI (1) | SI3359241T1 (es) |
WO (1) | WO2017062922A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3265115B1 (en) * | 2015-03-03 | 2022-06-22 | Radius Health, Inc. | Abaloparatide combined with alendronate for reducing non-vertebral bone fractures |
EP3481414B1 (en) | 2016-04-18 | 2021-11-03 | Radius Health, Inc. | Formulations of abaloparatide, transdermal patches thereof, and uses thereof |
US10996208B2 (en) | 2017-04-28 | 2021-05-04 | Radius Health, Inc. | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
WO2019059303A1 (ja) * | 2017-09-22 | 2019-03-28 | 旭化成ファーマ株式会社 | 薬物動態及び/又は安全性に優れるテリパラチド含有液状医薬組成物 |
CN107674113A (zh) * | 2017-10-20 | 2018-02-09 | 广东医科大学 | 一种小分子活性肽及其制备方法、及采用该活性肽的透皮贴剂的制备方法与其用途 |
CN110054679B (zh) * | 2018-01-18 | 2021-05-04 | 成都圣诺生物制药有限公司 | 一种合成Abaloparatide的方法 |
CN109602911B (zh) * | 2019-01-09 | 2020-11-10 | 厦门大学 | 硫酸钙晶须或其组合物在制备皮肤促渗剂中的用途 |
CN113453704A (zh) | 2019-02-28 | 2021-09-28 | 雷迪厄斯健康公司 | 阿巴帕肽的透皮递送系统及其使用方法 |
WO2021051082A1 (en) * | 2019-09-12 | 2021-03-18 | Radius Health, Inc. | Methods of improving spinal fusion with abaloparatide |
EP4110371A1 (en) | 2020-01-24 | 2023-01-04 | Radius Health, Inc. | Methods of stimulating bone growth with abalopartide and denosumab |
US12029562B2 (en) | 2021-04-14 | 2024-07-09 | Satio, Inc. | Dermal patch system |
US11877848B2 (en) | 2021-11-08 | 2024-01-23 | Satio, Inc. | Dermal patch for collecting a physiological sample |
US12053284B2 (en) | 2021-11-08 | 2024-08-06 | Satio, Inc. | Dermal patch for collecting a physiological sample |
US11964121B2 (en) | 2021-10-13 | 2024-04-23 | Satio, Inc. | Mono dose dermal patch for pharmaceutical delivery |
US12023156B2 (en) | 2021-10-13 | 2024-07-02 | Satio, Inc. | Dermal patch for collecting a physiological sample |
US12048543B2 (en) | 2021-11-08 | 2024-07-30 | Satio, Inc. | Dermal patch for collecting a physiological sample with removable vial |
WO2022249108A1 (en) * | 2021-05-25 | 2022-12-01 | Radius Health, Inc. | Treatment and prevention of osteoporosis in high body mass index individuals |
WO2023281447A1 (en) | 2021-07-07 | 2023-01-12 | Radius Health, Inc. | Methods of treating a cardiovascular ischemic event |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005014034A1 (en) * | 2003-07-14 | 2005-02-17 | Nps Allelix Corp. | Stabilized formulation of parathyroid hormone |
AU2007225056A1 (en) * | 2006-03-15 | 2007-09-20 | Alza Corporation | Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia |
RS56164B1 (sr) * | 2006-10-03 | 2017-11-30 | Radius Health Inc | Stabilna kompozicija koja sadrži pthrp i njene upotrebe |
WO2009054988A1 (en) * | 2007-10-23 | 2009-04-30 | Alza Corporation | Transdermal sustained release drug delivery |
WO2010111617A2 (en) * | 2009-03-27 | 2010-09-30 | Van Andel Research Institute | Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use |
CA2790923C (en) * | 2010-02-24 | 2017-10-31 | Toshiyuki Matsudo | Micro-needle device and preparation method |
US8637458B2 (en) * | 2010-05-12 | 2014-01-28 | Biodel Inc. | Insulin with a stable basal release profile |
MX2013012349A (es) * | 2011-04-22 | 2014-07-09 | Radius Health Inc | Metodo para suministro de farmaco para pth, pthrp y peptidos relacionados. |
US9623087B2 (en) * | 2011-11-30 | 2017-04-18 | 3M Innovative Properties Company | Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same |
CN102526220A (zh) * | 2012-01-10 | 2012-07-04 | 上海市中医医院 | 一种治疗期前收缩的中药贴剂及其制备方法和应用 |
US9581438B2 (en) * | 2012-12-31 | 2017-02-28 | General Electric Company | Systems and methods for control of a non-destructive testing system |
BR112016000937A8 (pt) * | 2013-07-18 | 2021-06-22 | Mannkind Corp | formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco |
CN108135962A (zh) * | 2015-10-07 | 2018-06-08 | 塞浦路迈德有限责任公司 | 用于口服递送肽类药物的药物制剂 |
-
2016
- 2016-10-08 SG SG11201802871UA patent/SG11201802871UA/en unknown
- 2016-10-08 MX MX2018004192A patent/MX2018004192A/es unknown
- 2016-10-08 CN CN201680064981.3A patent/CN108697881A/zh active Pending
- 2016-10-08 JP JP2018517605A patent/JP6867379B2/ja active Active
- 2016-10-08 LT LTEP16854524.2T patent/LT3359241T/lt unknown
- 2016-10-08 CN CN202210139738.0A patent/CN115025068A/zh active Pending
- 2016-10-08 CA CA3000533A patent/CA3000533C/en active Active
- 2016-10-08 EP EP21167699.4A patent/EP3909566A1/en not_active Withdrawn
- 2016-10-08 PT PT168545242T patent/PT3359241T/pt unknown
- 2016-10-08 IL IL287604A patent/IL287604B2/en unknown
- 2016-10-08 DK DK16854524.2T patent/DK3359241T3/da active
- 2016-10-08 AU AU2016334378A patent/AU2016334378B2/en active Active
- 2016-10-08 EP EP16854524.2A patent/EP3359241B1/en active Active
- 2016-10-08 ES ES16854524T patent/ES2881461T3/es active Active
- 2016-10-08 HU HUE16854524A patent/HUE055658T2/hu unknown
- 2016-10-08 WO PCT/US2016/056196 patent/WO2017062922A1/en active Application Filing
- 2016-10-08 KR KR1020187012690A patent/KR20180067573A/ko active Search and Examination
- 2016-10-08 SI SI201631273T patent/SI3359241T1/sl unknown
- 2016-10-08 PL PL16854524T patent/PL3359241T3/pl unknown
- 2016-10-08 RS RS20210890A patent/RS62394B1/sr unknown
- 2016-10-08 BR BR112018007159A patent/BR112018007159A2/pt active Search and Examination
-
2018
- 2018-03-28 IL IL258441A patent/IL258441B/en unknown
- 2018-04-09 US US15/948,953 patent/US20190091138A1/en not_active Abandoned
-
2021
- 2021-04-08 JP JP2021065966A patent/JP7146011B2/ja active Active
- 2021-07-14 HR HRP20211127TT patent/HRP20211127T1/hr unknown
- 2021-07-14 CY CY20211100636T patent/CY1124657T1/el unknown
- 2021-11-17 AU AU2021269361A patent/AU2021269361A1/en not_active Abandoned
-
2022
- 2022-09-20 JP JP2022149175A patent/JP2022174274A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018004192A (es) | Formulaciones de análogos de proteína relacionada con la hormona paratiroidea (pthrp), parches transdérmicos de las mismas y usos de las mismas. | |
PH12017501934A1 (en) | Methods for treating or preventing migraine headache | |
PH12017501057A1 (en) | Substituted 2-anilinopyrimidine derivatives as egfr modulators | |
MX2017001281A (es) | Material anisotropico biocompuesto, implantes medicos que lo comprenden y metodos para el tratamiento del mismo. | |
PH12016501966A1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
MY195427A (en) | Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease | |
EP4282479A3 (en) | Use of pridopidine to treat depression or anxiety | |
NZ751746A (en) | Combination therapy with controlled-release cnp agonists | |
MX2022009155A (es) | Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh). | |
MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
PH12019502363A1 (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
PH12018500315A1 (en) | Fumagillol heterocyclic compounds and methods of making and using same | |
EP4137147A3 (en) | Uses of abaloparatide in reducing fracture risk | |
MX2012006430A (es) | Preparaciones de combinacion que comprenden un antagonista de citocina y un corticosteroide. | |
IN2014MU00303A (es) | ||
GEP20207096B (en) | Substituted 2-thioxo-imidazolidin-4-ones and spiro analogues thereof, active anti-cancer ingredient, pharmaceutical com¬position, medicinal prepara¬tion, method for treating prostate cancer | |
MY176521A (en) | Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising the same and use thereof | |
MX2017000886A (es) | Tratamiento con cis-clomifeno de sofocos y perdida osea inducidos por privacion de androgeno terapeutica. | |
MD4780C1 (ro) | Urei asimetrice p-substituite şi utilizările medicale ale acestora | |
TW201613569A (en) | Composition consisting of kukoamine A and/or kukoamine B and method of using thereof | |
GB202203224D0 (en) | Electronic patch for transdermal delivery of medical compositions | |
GB201702549D0 (en) | Composition for improved bone fracture healing | |
TW201613921A (en) | Serine derivatives as ghrelin receptor agonists | |
MX2018003289A (es) | COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA AUMENTAR LA RECUPERACION DE TRAUMA DE TEJIDO BLANDO. | |
JO3394B1 (ar) | تركيبات ومنتجات للاستعمال في علاج كسور وعيوب العظام |